Search

Your search keyword '"Nolen, W. A."' showing total 493 results
Start Over Author "Nolen, W. A."
493 results on '"Nolen, W. A."'

1. The efficacy of lamotrigine in bipolar disorder: A systematic review and meta‐analysis.

Author

Haenen, N., Kamperman, A. M., Prodan, A., Nolen, W. A., Boks, M. P., and Wesseloo, R.

Subjects
LAMOTRIGINE, RANDOMIZED controlled trials, BIPOLAR disorder, HOSPITAL admission & discharge, COMPARATOR circuits
Abstract

Objective: To provide up‐to‐date clinical guidance on the efficacy of lamotrigine in bipolar disorder (BD). Methods: Eligible studies were identified during a systematic literature search according to PRISMA‐guidelines. We included randomized controlled trials (RCTs) and cohort studies that quantitatively assessed lamotrigine's efficacy in BD. We divided the included studies into three groups: 1. acute treatment of depression, 2. acute treatment of mania and hypomania, and 3. maintenance treatment. Analyses were stratified by control group (placebo vs active comparator) and treatment strategy (monotherapy vs add‐on treatment). Results: We included 20 RCTs (n = 1166 lamotrigine users) and 20 cohort studies (n = 11,141 lamotrigine users). Twenty‐four of these studies were included in meta‐analyses. During depressive episodes, greater decreases in depressive symptomatology were associated with initiation of lamotrigine as add‐on treatment than with placebo (SMD −0.30 [95% CI = −0.51, −0.10], df = 3, p = 0.004). Decreases in depressive symptomatology did not differ significantly between lamotrigine and the active comparator (SMD −0.28 [95% CI = −1.06, 0.50], df = 3, p = 0.488). As a maintenance treatment, lamotrigine was associated with a significantly lower relapse/recurrence rate than placebo (risk ratio (RR) 0.84 [95% CI = 0.71, 0.99], df = 2, p = 0.037). Relapse/recurrence rates did not differ significantly between lamotrigine and lithium (RR 1.06 [95% CI = 0.89, 1.25], df = 2, p = 0.513). A qualitative assessment of high‐quality register‐based studies found that lamotrigine was associated with lower hospital admission rates than other commonly used treatment regimes. Conclusions: There is substantial evidence for the efficacy of lamotrigine in BD, specifically as add‐on treatment during acute depressive episodes and as maintenance treatment for preventing relapse and recurrence. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Genome-wide association for major depressive disorder: a possible role for the presynaptic protein piccolo

Author

Sullivan, P F, de Geus, E J C, Willemsen, G, James, M R, Smit, J H, Zandbelt, T, Arolt, V, Baune, B T, Blackwood, D, Cichon, S, Coventry, W L, Domschke, K, Farmer, A, Fava, M, Gordon, S D, He, Q, Heath, A C, Heutink, P, Holsboer, F, Hoogendijk, W J, Hottenga, J J, Hu, Y, Kohli, M, Lin, D, Lucae, S, MacIntyre, D J, Maier, W, McGhee, K A, McGuffin, P, Montgomery, G W, Muir, W J, Nolen, W A, Nöthen, M M, Perlis, R H, Pirlo, K, Posthuma, D, Rietschel, M, Rizzu, P, Schosser, A, Smit, A B, Smoller, J W, Tzeng, J-Y, van Dyck, R, Verhage, M, Zitman, F G, Martin, N G, Wray, N R, Boomsma, D I, and Penninx, B W J H

Published
2009
Full Text
View/download PDF

16. Associations of plasma androgens with suicidality among men and women: A 9-year longitudinal cohort study: Associations of androgens with suicidality

Author

de Wit, A. E., De Boer, M. K., Bosker, F. J., van der Does, A. J.W., Gooren, L. J.G., Nolen, W. A., Penninx, B. W.J.H., Schoevers, R. A., Giltay, E. J., General practice, Internal medicine, Other Research, Psychiatry, APH - Mental Health, Amsterdam Neuroscience - Mood, Anxiety, Psychosis, Stress & Sleep, and APH - Digital Health

Abstract

Background: Testosterone has been implicated in suicidality in cross-sectional studies. Stress that coincides with a suicide attempt may alter androgen levels, so prospective studies are needed to exclude reverse causation. We aimed to examine the associations of plasma androgens with concurrent and future suicidality, and if present, whether these associations were mediated by a behavioral trait like reactive aggression. Methods: Baseline plasma levels of total testosterone, 5α−dihydrotestosterone, and androstenedione were determined with liquid chromatography–tandem mass spectrometry, and dehydroepiandrosterone-sulphate with a radioimmunoassay. Suicidality was assessed using the Suicidal Ideation Scale at baseline and after 2-, 4-, 6-, and 9-year follow-up. Men and women were analyzed separately, and potential confounders were considered. Results: Participants (N = 2861; 66.3% women) had a mean age of 42.0 years (range 18–65) and almost half (46.9%) fulfilled criteria for a major depressive or anxiety disorder. At baseline 13.2% of men and 11.2% of women reported current suicidal ideation. In participants who were non-suicidal at baseline, slightly more men than women reported suicidal ideation during follow-up (14.7% vs. 12.5%), whereas the reverse pattern was observed for suicide attempts (3.6% vs. 4.2%). None of the associations between androgens and current and future suicidality were significant. Limitations: Androgens were determined once, which may have been insufficient to predict suicidality over longer periods. Discussion: The lack of associations between plasma levels of androgens determined by ‘gold-standard’ laboratory methods with suicidality do not support previous cross-sectional and smaller studies in adult men and women with values within the physiological range.

Published
2020
Full Text
View/download PDF

20. Meta-analysis of genome-wide association data of bipolar disorder and major depressive disorder

Author

Liu, Y, Blackwood, D H, Caesar, S, de Geus, E J C, Farmer, A, Ferreira, M A R, Ferrier, I N, Fraser, C, Gordon-Smith, K, Green, E K, Grozeva, D, Gurling, H M, Hamshere, M L, Heutink, P, Holmans, P A, Hoogendijk, W J, Hottenga, J J, Jones, L, Jones, I R, Kirov, G, Lin, D, McGuffin, P, Moskvina, V, Nolen, W A, Perlis, R H, Posthuma, D, Scolnick, E M, Smit, A B, Smit, J H, Smoller, J W, St Clair, D, van Dyck, R, Verhage, M, Willemsen, G, Young, A H, Zandbelt, T, Boomsma, D I, Craddock, N, O'Donovan, M C, Owen, M J, Penninx, B W J H, Purcell, S, Sklar, P, and Sullivan, P F

Published
2011
Full Text
View/download PDF

24. Design of clinical trials in bipolar disorders: 8

Author

Tohen, M, Bowden, C, Berk, M, Berlanga, C, Andrade, C, Broich, K, Calabrese, J R, Frank, E, Geddes, J, Goodwin, G, Ha, K, Hirschfeld, B, Kanba, S, Keck, P, Lafer, B, Licht, R, Nierenberg, A, Nolen, W A, Suppes, T, Tamayo, J, Vieta, E, Yatham, L N, and Carlson, B

Published
2012

34. Antidepressiva: al decennia voor­geschreven én toch nog steeds bekritiseerd; een perspectief op oorzaken en oplossingen

Author

Ormel, J, Ruhé, H G, Bockting, C L H, Nolen, W, Schene, A H, Spijker, J, Ten Doesschate, M, Cramer, A O J, Verhaak, P, Spinhoven, P, Adult Psychiatry, Amsterdam Neuroscience - Mood, Anxiety, Psychosis, Stress & Sleep, APH - Mental Health, APH - Personalized Medicine, APH - Digital Health, Experimental Psychotherapy & Psychopathology, Interdisciplinair Centrum voor Psychopathologie en Emotieregulatie, and Clinical Cognitive Neuropsychiatry Research Program (CCNP)

Subjects
Antidepressant medication, Effectiveness, Long-term outcome
Abstract

BACKGROUND: From around 1980, antidepressants (ad) have increasingly been prescribed, for longer periods of time, especially selective serotonin reuptake inhibitors (ssris). Paradoxically, their effectiveness is still doubted, especially outside the psychiatric profession. AIM: To explain increase and offer a perspective on causes and solutions, and to indicate how to reach consensus. METHOD: Position paper with critical analysis and synthesis of relevant literature. RESULTS: The rise in AD prescriptions results from: 1. increased safety and ease of prescribing, 2. increased presentation and recognition of depression in primary care, 3. extension of indication criteria, 4. effective marketing strategies, and 5. effectiveness in acute phase (aad) and of relapse/recurrence prevention in continuation/maintenance phases (coad).Critics point to: 1. low added value of aad relative to placebo, 2. many drop-outs and non-responders, 3. relapse/recurrence prevention with coad works only for responders to aad, 4. relapse/recurrence after AD discontinuation often involves withdrawal symptoms, and 5. publication bias, selective reporting, selective patient selection, and suboptimal blinding, resulting in overestimated effectiveness and underestimated disadvantages.Factors that keep fueling the controversy are: 1. critics stress the net effectiveness of AD whereas proponents point at gross effectiveness which includes spontaneous recovery and placebo effect; 2. persistence of distrust in industry-funded rcts; 3. ideological positions, reinforced by conflicts of interest and selective citations; 4. lack of rcts with relevant long-term outcome measurements. CONCLUSION: Although consensus is difficult to achieve given the ideological component, there are options. Three factors are critically important: confer to establish which data convince the opposition, response prediction (what works for whom), and rcts with long-term functional outcomes.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results